These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38395466)

  • 1. Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    Wang JS; Wong T; Wu KA; Mullikin TC; Armstrong A
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38395466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
    Shah H; Ravi P; Sonpavde G; Jacene H
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1163-1175. PubMed ID: 36305305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Keam SJ
    Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Analyses of the Phase 3 VISION Trial of [
    Chi KN; Armstrong AJ; Krause BJ; Herrmann K; Rahbar K; de Bono JS; Adra N; Garje R; Michalski JM; Kempel MM; Fizazi K; Morris MJ; Sartor O; Brackman M; DeSilvio M; Wilke C; Holder G; Tagawa ST
    Eur Urol; 2024 Apr; 85(4):382-391. PubMed ID: 38185538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
    Liu X; Fang GC; Lu H; Shi ZD; Chen ZS; Han CH
    Drugs Today (Barc); 2023 Jan; 59(1):37-49. PubMed ID: 36811416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutetium-177-PSMA-617: A Vision of the Future.
    Chandran E; Figg WD; Madan R
    Cancer Biol Ther; 2022 Dec; 23(1):186-190. PubMed ID: 35220877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
    J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
    Parveen A; Fatima A; Fatima I; Khan IU; Shahid A
    Nucl Med Commun; 2023 Oct; 44(10):876-887. PubMed ID: 37440195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic Multidose Preparation of a Ready-to-Use
    Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
    Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.